EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity

Piotr Rzymski iD, Willis Gwenzi

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29453 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Piotr Rzymski und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Medicine, Poznan University of Medical Sciences, Poznań, Poland. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 121 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the approval of the first vaccines against respiratory syncytial virus (RSV) and a novel RSV‐neutralizing antibody, 2023 has been perceived as a game‐changing year in preventing severe outcomes of RSV infections in infants and the elderly. However, the costs of these pharmaceuticals are high, while RSV disproportionately impacts populations of low‐to‐middle‐income regions, which may continue to suffer from a lack of pharmaceutical measures for RSV prevention under health and socioeconomic disparities. This paper presents an overview of the characteristics, clinical results, and approval status of various RSV vaccines and anti‐RSV antibodies. It posits that wealthy nations cannot monopolize RSV immunoprophylaxis and should work jointly to make it available to lower‐income countries. An approach toward RSV immunoprophylaxis equity based on five points is offered: (1) integration of RSV vaccines and antibodies into the existing global humanitarian distribution systems, (2) using affordable RSV vaccine pricing models, (3) enforcing equity as a part of national and global public health strategy, (4) implementing equitable allocation frameworks for RSV immunoprophylaxis, and (5) promoting local manufacturing. Such a plan needs to be put into action as soon as possible to avoid delays in serving the populations with the highest needs related to RSV burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsInfantHumansAgedImmunizationAntibodies, Viral

Stichwörter der Autor:innen

low-to-middle-income countrieslower respiratory tract infectionsmonoclonal antibodiesrespiratory syncytial virusvaccine inequity

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Environmental Medicine, Poznan University of Medical Sciences, Poznań, Poland.
  • Biosystems and Environmental Enginering Research Group, Harare, Zimbabwe.
  • Alexander von Humboldt Fellow and Guest Professor at Grassland Science and Renewable Plant Resources, Faculty of Organic Agricultural Sciences, Universität Kassel, Witzenhausen, Germany.

ORCID-Profile: Piotr Rzymski

Zitieren

APA

Rzymski, P., & Gwenzi, W. (2024). Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity. Journal of Medical Virology. https://doi.org/10.1002/jmv.29453

Vancouver

Rzymski P, Gwenzi W. Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity. Journal of Medical Virology. 2024. doi:10.1002/jmv.29453

BibTeX
@article{Rzymski2024,
  author = {Rzymski, Piotr and Gwenzi, Willis},
  title = {Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29453}
}
Kostenlos starten →